Pulmonary hypertension and cardiovascular mortality in end-stage kidney disease: still some way to go before conclusive evidence

2021 ◽  
Author(s):  
Marieta P. Theodorakopoulou ◽  
Georgia Pitsiou ◽  
Afroditi K. Boutou
Keyword(s):  
Pulmonary Hypertension ◽  
Kidney Disease ◽  
Cardiovascular Mortality ◽  
Conclusive Evidence ◽  
End Stage Kidney Disease ◽  
End Stage

scholarly journals Pulmonary hypertension in patients with chronic and end-stage kidney disease

2013 ◽  
Vol 84 (4) ◽  
pp. 682-692 ◽  
Author(s):  
Meghan E. Sise ◽  
Andrew M. Courtwright ◽  
Richard N. Channick
Keyword(s):  
Pulmonary Hypertension ◽  
Kidney Disease ◽  
End Stage Kidney Disease ◽  
End Stage

scholarly journals Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists

2016 ◽  
Vol 21 (6) ◽  
pp. 1088-1096 ◽  
Author(s):  
Masato Nishimura ◽  
Toshiko Tokoro ◽  
Satoru Yamazaki ◽  
Tetsuya Hashimoto ◽  
Hiroyuki Kobayashi ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Kidney Disease ◽  
Endothelin Receptor Antagonists ◽  
Endothelin Receptor ◽  
End Stage Kidney Disease ◽  
Receptor Antagonists ◽  
Disease Effect ◽  
End Stage

Cardiovascular mortality in children and young adults with end-stage kidney disease

2002 ◽  
Vol 141 (2) ◽  
pp. 191-197 ◽  
Author(s):  
R.S. Parekh ◽  
C.E. Carroll ◽  
R.A. Wolfe ◽  
F.K. Port
Keyword(s):  
Young Adults ◽  
Kidney Disease ◽  
Cardiovascular Mortality ◽  
End Stage Kidney Disease ◽  
Children And Young Adults ◽  
End Stage

PULMONARY HYPERTENSION IN END STAGE KIDNEY DISEASE (ESKD) PATIENTS ON MAINTENANCE HEMODIALYSIS (MHD) VIA SURGICALLY CREATED ARTERIOVENOUS FISTULA.

2019 ◽  
Vol 3 (11) ◽  
Author(s):  
Hamad Jeelani ◽  
Manjuri Sharma ◽  
Manzoor A. Parry ◽  
Prodip.K. Doley ◽  
Gayatri Pegu
Keyword(s):  
Pulmonary Hypertension ◽  
Kidney Disease ◽  
Pulmonary Artery ◽  
Arteriovenous Fistula ◽  
Pulmonary Artery Pressure ◽  
Maintenance Hemodialysis ◽  
Systolic Pulmonary Artery Pressure ◽  
End Stage Kidney Disease ◽  
Venous Fistula ◽  
End Stage

Background Pulmonary hypertension is a disorder which worsens systemic diseases. One of the important underlying pathology is end stage chronic kidney disease The aim of this study was to assess the incidence of unexplained PHT, and to relate this to the cardiovascular status and arteriovenous fistula characteristics in ESKD patients on maintenance hemodialysis Methods: 159 patients with end stage kidney disease on maintenance hemodialysis were evaluated, 103 were excluded. Clinical, laboratory parameters were recorded. Systolic Pulmonary artery pressure and cardiac functions were evaluated by echocardiography. Flow across arteriovenous fistula was assessed by Doppler sonography. Patients were divided between the group with and without pulmonary hypertension. It was a cross sectional study. Result: Out of 159 patients, 56 patients who fulfilled inclusion criteria were evaluated, 36% had systolic pulmonary artery pressure of 35 mm Hg, mean age was 52.42 ± 9.12 years, 71.4% were males, and mean duration of end stage kidney disease was 33.66 ±11.56 months. Pulmonary hypertension patients were exposed to longer duration of hemodialysis therapy (p=0.0001) as compared to the patients with no pulmonary hypertension group, they also had a longer duration of functional Arterio venous fistula (p=0.0001), and flow across Arterio venous fistula was significantly more in pulmonary hypertension group (p=0.022), and these also had higher cardiac output (p=0.0001).  Patients with Pulmonary hypertension were significantly more anemic, had more hypoalbuminemia and more interdialytic weight gain. Conclusions:  Pulmonary hypertension is frequent in end-stage kidney disease patients on maintenance hemodialysis. It appears to be a late complication of hemodialysis with surgically created AVF with implications on cardiovascular status. Keywords: Arterio venous fistula (AVF), End-stage kidney disease (ESKD), Maintenance hemodialysis (MHD), pulmonary hypertension (PHT).Systolic pulmonary artery pressure (sPAP)

scholarly journals Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients

2013 ◽  
Vol 28 (suppl 4) ◽  
pp. iv181-iv187 ◽  
Author(s):  
B. Spoto ◽  
F. Mattace-Raso ◽  
E. Sijbrands ◽  
P. Pizzini ◽  
S. Cutrupi ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Cardiovascular Mortality ◽  
Effect Modification ◽  
End Stage Kidney Disease ◽  
Mortality Effect ◽  
End Stage

Eccentric Left Ventricular Hypertrophy and Sudden Death in Patients with End-Stage Kidney Disease

2015 ◽  
Vol 42 (2) ◽  
pp. 126-133 ◽  
Author(s):  
Camiel L.M. de Roij van Zuijdewijn ◽  
Romy Hansildaar ◽  
Michiel L. Bots ◽  
Peter J. Blankestijn ◽  
Marinus A. van den Dorpel ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Sudden Death ◽  
Left Ventricular Hypertrophy ◽  
Cardiovascular Mortality ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Convective Transport ◽  
End Stage Kidney Disease ◽  
All Cause Mortality ◽  
End Stage

Background/Aims: Both all-cause and cardiovascular mortality risks are extremely high in patients with end-stage kidney disease (ESKD). Sudden death accounts for approximately one-quarter of all fatal events. Left ventricular hypertrophy (LVH) is a known risk factor for mortality and can be divided in 2 types: concentric and eccentric. This study evaluated possible differences in all-cause mortality, cardiovascular mortality and sudden death between prevalent ESKD patients with concentric and eccentric LVH. Methods: Participants of the CONvective TRAnsport STudy (CONTRAST) who underwent transthoracic echocardiography (TTE) at baseline were analyzed. In patients with LVH, a relative wall thickness of ≤0.42 was considered eccentric and >0.42 was considered concentric hypertrophy. Cox proportional hazards models, adjusted for potential confounders, were used to calculate hazard ratios (HRs) of patients with eccentric LVH versus patients with concentric LVH for all-cause mortality, cardiovascular mortality and sudden death. Results: TTE was performed in 328 CONTRAST participants. LVH was present in 233 participants (71%), of which 87 (37%) had concentric LVH and 146 (63%) eccentric LVH. The HR for all-cause mortality of eccentric versus concentric LVH was 1.14 (p = 0.52), 1.79 (p = 0.12) for cardiovascular mortality and 4.23 (p = 0.02) for sudden death in crude analyses. Propensity score-corrected HR for sudden death in patients with eccentric LVH versus those with concentric LVH was 5.22 (p = 0.03). Conclusions: (1) The hazard for all-cause mortality, cardiovascular mortality and sudden death is markedly increased in patients with LVH. (2) The sudden death risk is significantly higher in ESKD patients with eccentric LVH compared to subjects with concentric LVH.

scholarly journals Association between physical activity and mortality in end-stage kidney disease: a systematic review of observational studies

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Pedro Martins ◽  
Elisa A. Marques ◽  
Diogo V. Leal ◽  
Aníbal Ferreira ◽  
Kenneth R Wilund ◽  
...  
Keyword(s):  
Physical Activity ◽  
Peritoneal Dialysis ◽  
Kidney Disease ◽  
Kidney Transplant ◽  
Cardiovascular Mortality ◽  
Observational Studies ◽  
End Stage Kidney Disease ◽  
Hand Search ◽  
All Cause Mortality ◽  
End Stage

Abstract Background End-stage Kidney Disease patients have a high mortality and hospitalization risk. The association of these outcomes with physical activity is described in the general population and in other chronic diseases. However, few studies examining this association have been completed in end-stage Kidney Disease patients, raising the need to systematically review the evidence on the association of physical activity with mortality and hospitalization in this population. Methods Electronic databases (EBSCO, Scopus and Web of Science) and hand search were performed until March 2020 for observational studies reporting the association of physical activity with mortality or hospitalization in adult end-stage Kidney Disease patients on renal replacement therapy (hemodialysis, peritoneal dialysis and kidney transplant). Methodological quality of the included studies was assessed using the Quality in Prognosis Studies tool. The review protocol was registered in PROSPERO (CRD42020155591). Results Eleven studies were included: six in hemodialysis, three in kidney transplant, and two in hemodialysis and peritoneal dialysis patients. Physical activity was self-reported, except in one study that used accelerometers. All-cause mortality was addressed in all studies and cardiovascular mortality in three studies. Nine studies reported a significant reduction in all-cause mortality with increased levels of physical activity. Evidence of a dose-response relationship was found. For cardiovascular mortality, a significant reduction was observed in two of the three studies. Only one study investigated the association of physical activity with hospitalization. Conclusions Higher physical activity was associated with reduced mortality in end-stage Kidney Disease patients. Future studies using objective physical activity measures could strengthen these findings. The association of physical activity with hospitalization should be explored in future investigations.

Sign in / Sign up

Export Citation Format

Share Document